UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
 
 
FORM 8-K

 

CURRENT REPORT Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported): August 17, 2016

 

 

Bionik Laboratories Corp.

(Exact Name of Registrant as Specified in Its Charter)

 

 

Delaware   000-54717   27-1340346
(State or Other Jurisdiction of
Incorporation or Organization)
  (Commission File Number)   (IRS Employer Identification
No.)

 

 

483 Bay Street, N105

Toronto, ON

 

 

 

M5G 2C9

(Address of Principal Executive Offices)

 

  (Zip Code)
Registrant’s Telephone Number, Including Area Code: (416) 640-7887
 
 
 
(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 3.02 Unregistered Sales of Equity Securities.

 

As previously announced by Bionik Laboratories Corp. (the “Registrant”), the Registrant consummated the acquisition of Interactive Motion Technologies, Inc., a Massachusetts corporation (“IMT”), on April 21, 2016. Pursuant to the terms of the acquisition of IMT, shares of IMT capital stock were automatically converted into the right to receive up to an aggregate of 23,650,000 shares of the Registrant’s common stock, par value $0.001 per share (the “Bionik Common Stock”).

 

On August 17, 2017, the Registrant caused the issuance of the remaining 11,310,157 shares of Bionik Common Stock not yet issued to the former IMT shareholders.

 

The Bionik Common Stock were issued pursuant to an exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended and Rule 506(b) promulgated thereunder.

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Date:  August 22, 2016

 

  BIONIK LABORATORIES CORP.
     
  By: /s/ Leslie Markow
  Name:  Leslie Markow
  Title:  Chief Financial Officer